CD274 and gastric cancer: The combination of PD-1/PD-L1 monoclonal antibodies and chemotherapy has established a new standard of care for the first-line treatment of patients with unresectable locally advanced or metastatic gastric cancer (GC) and gastro-oesophageal junction adenocarcinoma.